Why do some people get more sick from Covid? New research reveals the role genetics plays thespinoff.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thespinoff.co.nz Daily Mail and Mail on Sunday newspapers.
BioNTech, the German biotechnology company that developed a coronavirus vaccine with U.S. drugmaker Pfizer, has found some success using the same mRNA technique while attempting to treat multiple sclerosis in lab mice.
Corona-Mutationen: Forscher drängen auf konsequentere Maßnahmen in Europa ruhrnachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ruhrnachrichten.de Daily Mail and Mail on Sunday newspapers.
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
Collaborative study of BioNTech with TRON and the University Medical Center and Research Center for Immunotherapy at Johannes Gutenberg University of Mainz introduces novel non-inflammatory mRNA vaccine encoding disease-related autoantigens that suppressed disease activity in several complex mouse models of multiple sclerosis
Approach addresses key pitfalls in the treatment of autoimmune diseases such as the induction of systemic immune suppression
Approach can easily be tailored to individual disease-causing antigens of patients and confers bystander tolerance to address highly complex, polyclonal and rare autoimmune disease types
Represents the first application of BioNTech’s mRNA technology for the purpose of antigen-specific immune-modulation of autoimmune diseases, which further expands BioNTech’s diversified immunology pipeline into another category of disease relevant targets
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SEJanuary 7, 2021 GMT
Collaborative study of BioNTech with TRON and the University Medical Center and Research Center for Immunotherapy at Johannes Gutenberg University of Mainz introduces novel non-inflammatory mRNA vaccine encoding disease-related autoantigens that suppressed disease activity in several complex mouse models of multiple sclerosis
Approach addresses key pitfalls in the treatment of autoimmune diseases such as the induction of systemic immune suppression
Approach can easily be tailored to individual disease-causing antigens of patients and confers bystander tolerance to address highly complex, polyclonal and rare autoimmune disease types